Clinical Trial: A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07219511) titled 'A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)' on Oct. 17.

Brief Summary: A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)

Study Start Date: Oct. 31

Study Type: INTERVENTIONAL

Condition: Heart Heart Failure With Preserved Ejection Fraction (HFPEF)

Intervention: DRUG: VS-041

VS-041 high dose, VS-041 low dose or Placebo tablet BID

OTHER: Placebo

Placebo to match VS-041

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Vasa Therapeutics

Published by HT Digital Con...